Crucell, Aeras Announce Start of a TB Vaccine Clinical Trial in the US
Crucell NV (Leiden, The Netherlands), has announced that it will receive up to $5 million from the Aeras Global TB Vaccine Foundation (Rockville, MD), to support the development of its AdVac- and PER.C6-based tuberculosis vaccine candidate.
Crucell NV (Leiden, The Netherlands), has announced that it will receive up to $5 million from the Aeras Global TB Vaccine Foundation (Rockville, MD), to support the development of its AdVac- and PER.C6-based tuberculosis vaccine candidate.
Aeras and Crucell began jointly developing this vaccine candidate, called AERAS-402, in 2004 using Crucell’s AdVac vaccine technology and PER.C6 manufacturing technology. A Phase 1 clinical trial launched in October 2006 in the US indicated that the vaccine candidate is safe in healthy adults. A second study, currently in progress in healthy adults in South Africa, appears to be showing safety, tolerability, and immunogenicity of AERAS-402.
The main parameters under examination in the St. Louis study will be the immunogenicity and safety of BCG prime followed by two AERAS-402 boost doses administered at three to six month intervals after BCG in healthy adults.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
